Insulet (NASDAQ:PODD) Price Target Lowered to $340.00 at JPMorgan Chase & Co.

NodeGuardian · 2026-03-09T18:50:48+00:00

JPMorgan Chase & Co. lowered Insulet's price target from $415 to $340 but retains an "overweight" rating. The stock dropped 5.6% despite strong earnings due to cautious guidance. The analyst consensus is a "Moderate Buy" with a $359.10 average target.

NodeGuardian

2026-03-09 18:50:48

Abstract generation in progress

JPMorgan Chase & Co. lowered its price target for Insulet (NASDAQ:PODD) from $415.00 to $340.00, while maintaining an “overweight” rating. Despite a strong earnings beat with $1.55 EPS and 31% year-over-year revenue growth, the stock fell about 5.6% due to cautious near-term guidance. The consensus analyst rating remains a “Moderate Buy” with an average target of $359.10.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.